Evergreen Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Evergreen Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$721K	Buy	2,280 +4	+0.2%	+$943	0.01%	695
2026 Q1	$454K	Hold	2,276	–	–	0.01%	848
2025 Q4	$430K	Sell	2,276 -22	-1%	-$4.23K	0.01%	835
2025 Q3	$407K	Buy	2,298 +499	+28%	+$74.2K	0.01%	755
2025 Q2	$205K	Buy	+1,799	New	+$192K	0.01%	1030

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Evergreen Capital Management's LGND Position: Q2 2026 in Review

Evergreen Capital Management increased its Ligand Pharmaceuticals (LGND) stake by 0.18% in Q2 2026, buying an estimated $943 and bringing the position to 2,280 shares worth $721K. The position accounts for 0.01% of the portfolio, ranked #695.

Evergreen Capital Management first reported a position in LGND in Q2 2025 and has held it in 5 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Evergreen Capital Management held 2,280 shares of Ligand Pharmaceuticals worth $721K as of Q2 2026.
Evergreen Capital Management bought 4 Ligand Pharmaceuticals shares in Q2 2026, an estimated $943.
Ligand Pharmaceuticals made up 0.01% of Evergreen Capital Management's portfolio in Q2 2026, its #695 holding.
Evergreen Capital Management first reported a position in Ligand Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Evergreen Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.